Sonic Hedgehog inhibition as a strategy to augment radiosensitivity of hepatocellular carcinoma

J Gastroenterol Hepatol. 2015 Aug;30(8):1317-24. doi: 10.1111/jgh.12931.

Abstract

Background and aim: Sonic Hedgehog (SHH) is a regulator in tumorigenesis of hepatocellular carcinoma (HCC). This study aimed to determine whether radiation-induced SHH signaling occurs in HCC and whether SHH inhibitor acts as a radiosensitizer.

Methods: The in vitro effects of combining SHH ligand (recombinant human SHH) or inhibitor (cyclopamine) with irradiation were evaluated in the human HCC cell lines, Huh-7 and PLC/PRF/5, and murine cell line BNL. Cell survival and apoptosis were measured using a colony formation assay, annexin-V staining, and poly (ADP-ribose) polymerase activation. Western blotting and immunofluorescence staining were used to detect protein expression. The in vivo response to radiotherapy and/or cyclopamine was tested in BALB/c mice bearing an orthotopic allogeneic tumor.

Results: Treatment of HCC cells with irradiation and SHH ligand had a protective effect on clonogenic cell survival. Treatment with irradiation and cyclopamine was a more potent inhibitor of cell proliferation than either modality alone. The antiproliferative activity of cyclopamine was attributable to apoptosis induction. Radiation dose-dependently upregulated the expression of Gli-1 (a transcription factor induced by SHH), and this effect was observed mainly in the nucleus. When combined with cyclopamine, irradiation inhibited Gli-1 and increased DNA double-strand breakage. Radiotherapy increased SHH and Gli-1 expression in allogeneic tumor. When compared with radiotherapy alone, cyclopamine with radiotherapy reduced the mean tumor size of orthotopic tumors by 67% (P < 0.05).

Conclusion: Combining an SHH inhibitor with radiotherapy may enhance HCC cell and orthotopic tumor radiosensitivity.

Keywords: Sonic Hedgehog; hepatocellular carcinoma; radiotherapy; sensitization.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Apoptosis / radiation effects
  • Carcinogenesis / genetics
  • Carcinoma, Hepatocellular / genetics*
  • Carcinoma, Hepatocellular / pathology
  • Carcinoma, Hepatocellular / physiopathology
  • Carcinoma, Hepatocellular / radiotherapy*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cell Proliferation / radiation effects
  • Cell Survival / drug effects
  • Cell Survival / radiation effects
  • Combined Modality Therapy
  • DNA Breaks, Double-Stranded
  • Disease Models, Animal
  • Dose-Response Relationship, Radiation
  • Gene Expression / radiation effects
  • Hedgehog Proteins / antagonists & inhibitors*
  • Humans
  • Ligands
  • Liver Neoplasms / genetics*
  • Liver Neoplasms / pathology
  • Liver Neoplasms / physiopathology
  • Liver Neoplasms / radiotherapy*
  • Mice
  • Mice, Inbred BALB C
  • Molecular Targeted Therapy*
  • Neoplasm Transplantation
  • Radiation Tolerance / drug effects*
  • Radiation Tolerance / genetics*
  • Radiation-Sensitizing Agents / pharmacology*
  • Radiation-Sensitizing Agents / therapeutic use*
  • Recombinant Proteins
  • Signal Transduction / genetics
  • Signal Transduction / physiology
  • Transcription Factors
  • Veratrum Alkaloids / pharmacology*
  • Veratrum Alkaloids / therapeutic use*
  • Zinc Finger Protein GLI1

Substances

  • GLI1 protein, human
  • Hedgehog Proteins
  • Ligands
  • Radiation-Sensitizing Agents
  • Recombinant Proteins
  • SHH protein, human
  • Transcription Factors
  • Veratrum Alkaloids
  • Zinc Finger Protein GLI1
  • cyclopamine